Registered title, quoted from ClinicalTrials.gov
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Guangzhou Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07318636, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically and/or cytologically confirmed resectable stage IB to IIIA non-small cell lung cancer (NSCLC) according to AJCC 8th edition.
Inclusion criterion 3
Female participants of childbearing potential must have a negative pregnancy test prior to initiation of study treatment.
Inclusion criterion 10
Major cardiovascular events, unstable arrhythmia, or unstable angina within 3 months prior to study treatment initiation.
Exclusion criterion 7
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Inclusion criterion 8
No sensitizing EGFR mutations (exon 19 deletion, exon 21 L858R) and no ALK gene rearrangement.
Inclusion criterion 5
At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Inclusion criterion 6
Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use effective contraception during the study.
Exclusion criterion 8
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07318636, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Able to understand and voluntarily sign the written informed consent form (ICF).
- Male or female patients aged ≥18 years.
- Histologically and/or cytologically confirmed resectable stage IB to IIIA non-small cell lung cancer (NSCLC) according to AJCC 8th edition.
- Treatment-naïve NSCLC (no prior systemic anticancer therapy).
- No sensitizing EGFR mutations (exon 19 deletion, exon 21 L858R) and no ALK gene rearrangement.
- At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Estimated life expectancy of more than 6 months.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Adequate bone marrow, liver, and renal function.
- Female participants of childbearing potential must have a negative pregnancy test prior to initiation of study treatment.
Exclusion Criteria:
- Prior receipt of any systemic anticancer therapy.
- Known sensitizing EGFR mutations or ALK gene rearrangements.
- Active, known, or suspected autoimmune disease.
- Interstitial lung disease.
- Any medical condition, therapy, or laboratory abnormality that, in the opinion of the investigator, could confound the study results, interfere with the participant's ability to comply with study procedures, or is not in the best interest of the participant.
- Locally advanced unresectable or metastatic NSCLC.
- Major cardiovascular events, unstable arrhythmia, or unstable angina within 3 months prior to study treatment initiation.
- Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use effective contraception during the study.
- Any other condition judged by the investigator to make the participant unsuitable for clinical trial participation.
Quoted from ClinicalTrials.gov, NCT07318636, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07318636, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.